GW Pharmaceuticals PLC | Mutual Funds
Mutual Funds that own GW Pharmaceuticals PLC
Biotech Growth Trust Plc (The)
1,259,838
0.37%
-86,467
2.21%
09/30/2017
Stichting Pensioenfonds ABP (Global Equity Portfolio)
776,747
0.23%
-299,202
0%
03/31/2018
Mirae Asset Tiger NASDAQ Bio ETF
3,986
0%
1,216
0.39%
04/30/2018
Deka - EuropaPotential TF
8
0%
0
0%
06/29/2018
Deka - EuropaPotential CF
8
0%
0
0%
06/29/2018
CREF Stock Account
8
0%
0
0%
03/31/2018
DekaLux - Mid Cap TF
7
0%
0
0%
03/29/2018
Sparinvest INDEX Europe Small Cap
4
0%
0
0%
08/31/2018
FlexShares Morningstar Dev. Mrkts. (ex-US) Factor Tilt Index
1
0%
0
0%
09/06/2018
FDC SICAV - Actions Monde Small Cap - Indexe
0
0%
-5,977
0%
12/31/2016
| Address |
Sovereign House
Cambridge Cambridgeshire CB24 9BZ
United Kingdom
|
|
Employees
|
- |
| Website |
http://gwpharm.co.uk |
| Updated |
07/08/2019 |
| GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. |
